To describe current practices around initiation and follow-up care of stimulant treatment among stimulant-treated children in a nationwide survey among parents.
Introduction
Stimulants are the first choice pharmacotherapeutic intervention in the treatment of attention-deficit/hyperactivity disorder (ADHD) and the most frequently used psychotropic medication in children. The considerable increase of stimulant use in several Western countries in the nineties, as evident from prescription database research, has resulted in public concern about the appropriateness of stimulant treatment in children [1] [2] [3] [4] . These concerns were further heightened by the increased use in preschoolers and the increased duration of stimulant therapy [1, 3] . Although stimulants have been used since the 1960s, still the impact of long-term stimulant use is unclear [5] . The largest and longest randomized clinical trial of stimulant medication in children with ADHD had a duration of 14 months and showed continuous effectiveness and frequent, yet minimal harmful, side-effects [6] .
However, 14 months is still relatively short compared to the duration of time that many children are prescribed stimulant medication.
As the general prevalence increased, both in the lay media and medical journals questions were raised about the appropriateness of the treatment and the competence of the initiating physician [2, 7, 8] . A study from the USA reported that family practitioners prescribed stimulants more often than pediatrics and psychiatrists, and Miller et al. reported that between 1990 and 1996 41% of the first stimulant prescriptions in Canada were prescribed by GPs [2, 9] . In the Netherlands, the lay media claimed excessive prescribing of stimulant medication by GPs, which caused considerable concern and discussion.
Thereupon the Health Council of the Netherlands stated that initiation of stimulant treatment should be restricted to physicians experienced and trained in diagnosing and treating ADHD and co-morbid disorders, like child psychiatrists and pediatricians [10] .
Several treatment guidelines for ADHD recommend that multimodal interventions, most of the time including stimulant medication, should be available to all children and usually are indicated [11] [12] [13] [14] . Guidelines mostly rely on the results of the largest randomized controlled trial of ADHD treatment, the Multimodal Treatment Study of Children with ADHD [6] . In the MTA stimulant medication alone and stimulants combined with behavioral therapy were found to be superior in improving ADHD symptoms compared to care as usual. Several factors were thought to account for this difference, like monthly check-ups and dose titration strategies in the medication management arm, while children treated in the care as usual arm visited their physician on average 2.3 times per year. It is generally agreed that optimal stimulant treatment presupposes regular contact of the treating physician with the child, parents and school, using rating scales for monitoring effectiveness, adjusting stimulant dose if necessary and looking after possible side-effects. However, studies from the USA suggest that treatment services offered to children with ADHD may be determined by the 28 type of treating physician rather than by established standards of care [9, 15] . Hence, the gap between what is classified as care as usual in the MTA study and the care as usual in any regional setting warrants further investigation. Most in-depth research on initialization and follow-up of stimulant treatment is limited to groups of children selected for their diagnosis with ADHD, or their visits to certain officebased physicians [16] [17] [18] [19] . Consequently, the results of these studies cannot be generalized to the total population of stimulant-treated children, nor to an international setting. The societal turmoil in The Netherlands, however, was based on studies from North America, as no information was available on the Dutch situation. Hence a nationwide survey was initiated to describe current practices around initiation and follow-up of stimulant treatment in children. Parents of stimulant-treated children were inquired after the initiation and follow-up care of stimulant treatment, using community pharmacies for recruitment to avoid bias for the initiating or treating physician.
Methods
The survey included only parents of stimulant-treated children in 2003. To obtain a nationwide sample of stimulant users irrespective of the prescribing physician, pharmacies were used for detecting stimulant users in their pharmacy information system and for sending a questionnaire to their parents or caregivers. The study design and response patterns have been described in detail elsewhere [20] .
In short, a nationwide sample of 115 pharmacies detected current users of methylphenidate and dexamphetamine in their computer system and sent a questionnaire to the parents in The questionnaire contained open-ended and multiple choice questions and was tested among ten parents. Questions dealt with the key symptoms for stimulant treatment and the type of physician involved in prescribing stimulants. We also asked the parents whether their child would visit a doctor or was expected to visit a doctor with regard to the use of stimulant medication. In case the child received this follow-up care, parents were questioned about the frequency of visits and about physical examination and evaluation of effectiveness of stimulant treatment during the most recent visit. Furthermore, questions were asked about the child's age and sex, education, psychiatric diagnoses, co-medication and nonpharmacological therapy. The protocol was approved by the Medical Ethics Board of the University Medical Centre Groningen. Questionnaires were regarded unsuitable for analysis when the child was 16 years or older or when children of 12 years or older had not given written permission to send in the questionnaire.
To investigate factors that might be associated with receiving follow-up care Pearson Chi Square or one-way ANOVA tests (two-tailed) were used and a p-value < 0.05 was considered statistical significant. Questionnaires were analyzed using SPSS 11.0.
Results

Demographic characteristics
Of 1307 questionnaires sent out by 115 pharmacies, 924 returned questionnaires were suitable for analysis (response rate: 71%). In 86% of the cases questionnaires were completed by the child's mother. Dutch was the first language for nearly all responding parents (97%). The median age of the stimulant-treated children was 10 years and the maleto-female ratio was approximately 5.5:1 (Table 1) .
Diagnosis and treatment
The vast majority of the children (91%) were diagnosed with attention-deficit/hyperactivity disorder (ADHD) ( Table 1) . Parent who reported no ADHD diagnosis, reported mainly pervasive developmental disorder (44/84) and learning disorder (12/84) for diagnosis.
Furthermore, 11 of the 84 parents reported that no diagnosis was established yet. Twentyeight percent of the children had two or more psychiatric diagnoses. Of the 924 children, 540 had received non-pharmacological therapy besides stimulants (58%). Therapy consisted of non-intensive training with a maximum of 2 hours per week in 49% of these children, and/or physical therapy (34%) and/or intensive training for more than 2 hours per week (27%).
Parents received counseling for the behavioral problems of their child in 571 cases (62%), being primarily individual parent training (78%), home training (33%) and/or group-based parent training (20%). In almost a quarter of the cases (23%), neither child nor parents received other therapy besides stimulants. 21% of the children received psychotropic comedication, including melatonin. In case melatonin was excluded 12% received psychotropic co-medication. Melatonin (10.8%) and antipsychotics (7.3%) were the most frequently mentioned co-medication.
According to the parents, the child's inattention, hyperactivity, impulsiveness and/or learning problems were the key symptoms for stimulant treatment (Table 1) . Stimulant treatment was primarily initiated by child psychiatrists and pediatricians. GPs provided repeat prescriptions for 61% of the children, child psychiatrists and pediatricians for 30% and 21% respectively. Fifteen percent of the children received repeat prescriptions from 2 or more different types of physicians. According to 264 parents (29%), their child experienced annoying side effects; sleep problems (52%) and loss of appetite (42%) were the most frequently mentioned side effects by these parents. More than half of the children used stimulants for over two years.
Follow-up care
Almost one out of five children (19%) did not receive follow-up care concerning treatment with stimulants ( Table 1 ), meaning that no appointment was scheduled or requested by the medical doctor according to the parents. Children who received the first stimulant prescription and repeat prescriptions from the same type of physician, were significantly more likely to receive follow-up care than children with a transfer of prescribers (Table 2) .
32 Furthermore, children receiving follow-up care were slightly younger (p=0.02). No statistical significant association was found between receiving follow-up care and gender, special education, time since first stimulant prescription, the number of diagnoses and use of psychotropic co-medication.
The 732 children who received follow-up care visited a physician on average twice a year, usually a child psychiatrist or a pediatrician (Table 3) , and 5.3% visited two different types of physicians for follow-up care. The mean number of follow-up visits decreased with an increased period of stimulant use, from 3 visits per year for children who had used stimulants less than one year to 2 visits per year for children who had used stimulants for 1-2 years and 2 years or longer (one-way ANOVA, df 2, p<0.001).
During follow-up visits pediatricians (93%) performed physical check-ups significantly more often than GPs (82%), child psychiatrists (80%) and other physicians (59% 
Discussion
Stimulant treatment was primarily initiated by specialists (e.g. child psychiatrists and pediatricians), while GPs took care of most of the repeat prescriptions. Nearly one in every five current stimulant-treated children did not receive any follow-up care aimed at their stimulant use.
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In our study, 12% of the parents reported that stimulant treatment had been initiated by a GP, which is a low percentage compared to 41% in Canada [2] . Therefore, general concerns about the competence of the initiating physician appear to be unnecessary for the Dutch situation.
According to the parents, stimulants were mainly used for ADHD, the indication for which these drugs are licensed. Of the children 28% had two or more psychiatric diagnoses, which is a low percentage compared to co-morbidity rates of over 50% reported elsewhere [21, 22] . The presently reported low figures may be partially explained by under diagnosis of psychiatric disorders in this general population, a population in which not all children are thoroughly screened by child psychiatrists.
For the majority of the children (77%) stimulant treatment was or had previously been combined with non-pharmacological therapy for the child and/or the parents. A study from the USA reported that in 47% of the visits stimulant users received mental health counseling and 22% psychotherapy [17] . The 21% psychotropic co-medication in the present study is consistent with the 19 -25% in other studies, although it is unclear if these two studies included melatonin [23, 24] . Another study from the Netherlands, based on a prescription database however, reported only 15% psychotropic co-medication among stimulant users [25] . Part of this difference may be attributable to incomplete data on melatonin as OTC medication in prescription databases. We were surprised to find that over 10% of the stimulant-treated children used melatonin, probably for sleep problems. Like many other hypnotics, melatonin is not approved for use in children. Actually, melatonin is not approved in the Netherlands at all, and safety data are lacking. All the more a reason for carefully monitoring these children. As far as we know, no literature is available about the prevalence of melatonin use in other countries. It would be interesting to study whether the frequent use of melatonin in stimulant-treated children is a typical Dutch phenomenon.
The fact that almost 20% of the stimulant-treated children in our study were not monitored is worrisome. Transfer of prescribing responsibility, in most cases from specialist to GP, increased the risk of not receiving any follow-up care. These findings call for efforts to improve collaboration between primary and secondary care. At this point we agree with Ball et al. that GPs might take over prescribing responsibility after initiation and perform physical monitoring, but only in close liaison with the treating specialist [26] . However, our data show that having one prescriber is not a guarantee for receiving follow-up care. So, all prescribers, in particular child psychiatrists and GPs, need to reconsider the follow-up care they provide in addition to improving collaboration between specialists and GPs/other care providers.
The children who did receive follow-up care visited a physician on average twice a year, which is similar to a study from the USA among children, with recently identified 35 ADHD, but in sharp contrast to the monthly check-ups in medication management arms of the MTA study [6, 19] . Pediatricians were more likely to measure weight, length and blood pressure during a follow-up visit than child psychiatrists and GPs, probably because pediatricians perform these check-ups routinely. Other studies also reported differences between different types of physicians and type of follow-up services offered [9, 15, 17] .
However, opposite to our findings, Hoagwood et al reported follow-up care was more likely to be provided by psychiatrists than GPs and pediatricians [9, 17] .
Our study described initiation and follow-up care of stimulant treatment in a populationbased sample of stimulant-treated youths in the Netherlands. However, the way study participants were recruited has some limitations. For some children initiation of stimulant treatment occurred more than two years before the survey, which might have introduced recall bias in their parents. It should be mentioned that the questionnaire was not available in minority languages, which might have hindered non-native speakers to respond. Another limitation of our study is that no information was available on how the child was assessed, no statements could be made about the appropriateness of the ADHD diagnosis.
Nonetheless, the median age and male-to-female ratio in our sample recruited via community pharmacies, were very similar to those reported in studies based on large dispensing databases, on visits to office-based physicians and in children identified with ADHD [2, 16, 25, 27] . In the presented analyses, the nesting of children in pharmacies was ignored. This was done for several reasons: first the limited number of children per pharmacy (needed to guarantee high participation rates of the pharmacies) would have given numerical problems and secondly, many of the variables of interest were nominal.
Lastly, there was no evidence of a pharmacy effect as investigated by: looking into variation, chi-square tests, and ANOVAs.
Conclusions
Stimulant treatment in the Netherlands is mainly initiated by specialists like child psychiatrists and pediatricians. Thus, major concern about GPs starting treatment frequently appears unnecessary. However, our study demonstrated that we should not only focus on the initiation of stimulant treatment, but even more on the follow-up care. This follow-up care
for stimulant-treated children in the Netherlands appeared poor, suggesting an urgent need for improvement. A closer collaboration between primary and secondary care, supported by multidisciplinary guidelines clearly describing the criteria of good follow-up care and the responsibilities of different professionals involved, may be a good start to this improvement.
